Guardant Health, Inc. - Common Stock (NQ:GH)

165.88 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Guardant Health Earnings: What To Look For From GH

May 05, 2026

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after the bell. Here’s what you need to know. Guardant Health beat an...

Via StockStory

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

May 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

April 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

April 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗

February 19, 2026

Via Chartmill

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know

April 06, 2026

What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...

Via StockStory

Topics Government Stocks

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Why Is Guardant Health (GH) Stock Soaring Today

March 31, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.9% in the afternoon session after the company announced that real-world evi...

Via StockStory

Topics Government Stocks

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

March 30, 2026

From Guardant Health, Inc.

Via Business Wire

Why Guardant Health (GH) Stock Is Falling Today

March 27, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 3% in the afternoon session after major indices including the S&P 500 and Dow J...

Via StockStory

Topics Artificial Intelligence Economy Government

3 Growth Stocks We Think Twice About

March 26, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)...

Via MarketMinute

Topics Supply Chain

3 Reasons to Avoid GH and 1 Stock to Buy Instead

March 19, 2026

What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid ...

Via StockStory

Topics Supply Chain

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

March 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

March 16, 2026

From Guardant Health, Inc.

Via Business Wire

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

Via The Motley Fool

Topics Regulatory Compliance

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.

Via The Motley Fool

Topics Regulatory Compliance

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

March 10, 2026

From Guardant Health, Inc.

Via Business Wire

1 Russell 2000 Stock on Our Watchlist and 2 We Question

March 05, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Topics Supply Chain

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

March 04, 2026

From Guardant Health, Inc.

Via Business Wire

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

March 03, 2026

From Guardant Health, Inc.

Via Business Wire

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

Via StockStory

Topics Economy Stocks

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2026

From Guardant Health, Inc.

Via Business Wire

The Great Rotation: Small-Caps Break Record Highs as the 'Catch-Up' Trade Ignites

February 26, 2026

In a dramatic shift that has caught Wall Street’s heavy hitters off guard, the Russell 2000 index has surged to unprecedented heights in early 2026, signaling the definitive arrival of the long-awaited...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Topics Economy Government World Trade

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

February 19, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 39.4% year on year to $281.3 million. The company’s full-year revenue...

Via StockStory

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

February 19, 2026

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.